AstraZeneca has agreed to acquire Belgium-based EsoBiotec for up to $1 billion, with an initial payment of $425 million and additional milestone-based payments of up to $575 million.
AstraZeneca will present AMPLIFY Phase III trial results, reinforcing CALQUENCE® as a leading BTK inhibitor in frontline chronic lymphocytic leukemia with a fixed-duration regimen.
The ECHO Phase III trial demonstrated that CALQUENCE (acalabrutinib) combined with bendamustine and rituximab significantly reduced disease progression or death risk by 27% compared to standard chemoimmunotherapy in previously untreated mantle cell lymphoma patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.